Immune Thrombocytopenia natural history, complications and prognosis: Difference between revisions
some parts of natural history |
No edit summary |
||
| Line 24: | Line 24: | ||
===Complications=== | ===Complications=== | ||
*Common complications of | *Common complications of immune thrombocytopenia include: | ||
** | **Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.) | ||
** | **Infection ( due to splenectomy or immunosuppressive medications) | ||
**[Complication 3] | **[Complication 3] | ||
===Prognosis=== | ===Prognosis=== | ||
*Prognosis is generally excellent/good/poor, and the | *Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.<ref name="KohliChaturvedi20192">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> | ||
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | *Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | ||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | ||
Revision as of 02:44, 1 February 2021
|
Immune Thrombocytopenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Immune Thrombocytopenia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Immune Thrombocytopenia natural history, complications and prognosis |
|
FDA on Immune Thrombocytopenia natural history, complications and prognosis |
|
CDC on Immune Thrombocytopenia natural history, complications and prognosis |
|
Immune Thrombocytopenia natural history, complications and prognosis in the news |
|
Blogs on Immune Thrombocytopenia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding.[1][2]
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of immune thrombocytopenia include:
- Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.)
- Infection ( due to splenectomy or immunosuppressive medications)
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.[3]
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ . doi:10.2147/JBM.S289390. Check
|doi=value (help). Missing or empty|title=(help) - ↑ Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
- ↑ Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.